Protalix BioTherapeutics to report Q3 2026 financial results on November 10
Biopharmaceutical company Protalix BioTherapeutics will release its third-quarter financial results and provide a corporate update on November 10, 2026.
Protalix BioTherapeutics, an Israel-based biopharmaceutical company, is scheduled to announce its financial results for the quarter ended September 30, 2026, on November 10. The announcement will include a management briefing on recent regulatory developments and ongoing business operations.
Protalix utilizes its proprietary ProCellEx platform, a plant cell-based expression system for producing recombinant proteins. Key focus areas for investors include the company’s pipeline, notably its PRX-115 and PRX-119 programs, and the commercial performance of its partnered products, Elelyso and Elfabrio.
The company will host a conference call and live webcast at 8:00 a.m. ET to discuss the figures. A replay of the presentation will remain available on the company's investor relations website for two weeks following the event.